Kala Pharmaceuticals’ dry eye treatment candidate KPI-121 0.25% met both of its primary efficacy endpoints in the phase 3 STRIDE 3 trial, according to a press release.
KPI-121 0.25% (loteprednol etabonate ophthalmic suspension), which the company plans to commercialize under the name Eysuvis, uses Kala’s Amplify mucus-penetrating drug delivery technology.
A statistically significant improvement in ocular discomfort severity was demonstrated at day 15 in the overall intent-to-treat population (P = .0002) as well as in a predefined subgroup of patients with more severe ocular
Uncategorized